BioSpace News Archive

Iovance Biotherapeutics, Inc. today announced oral and poster presentations reporting clinical data and trial design for tumor infiltrating lymphocyte (TIL) cell therapies at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting in Boston, Massachusetts, November 8-12, 2022.

NeoImmuneTech, Inc. today announced it will present development progress of its main asset, NT-I7 (efineptakin alfa), across five presentations at the Society for Immunotherapy of Cancer (SITC) annual meeting, to be held in Boston , November 8, 2022.

KaliVir Immunotherapeutics, Inc today announced that it will be presenting data on its product candidate VET3-TGI at the 37th Annual Meeting of the Society for Immunology of Cancer (SITC), taking place November 8-12, 2022.

BIOREM Inc. announced several new orders totalling $7.1 million. The orders are for air emission abatement projects in North America and continue to increase BIOREM’s order backlog to a record $44.5 million, its highest point since the Company was founded in 1990.

AbCellera (Nasdaq: ABCL) today announced a presentation at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, to be held virtually and at the Boston Convention & Exhibition Center from November 8 to 12, 2022.

Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the acceptance of two abstract for poster presentations at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, which is taking place both virtually and in-person at the Boston Convention and Exhibition Center in Boston, MA, from November 8 – 12, 2022.

Apnimed today announced that John Cronin, M.D., has joined the company as Senior Vice President, Clinical Development.

Asher Biotherapeutics, Inc. today announced that it will present preclinical data for two of its cis-targeted immunotherapies, AB248 and AB821, at the Society for Immunotherapy in Cancer (SITC) 37th Annual Meeting, being held in Boston, Massachusetts, on November 8-12, 2022.

Adicet Bio to Present Preclinical Data from Allogeneic Gamma Delta T Cell Pipeline Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting.

Artiva Biotherapeutics, Inc. announced today that an abstract highlighting further in vivo and in vitro preclinical data for AB-101, the Company’s clinical-stage ADCC-enhancer product candidate, was accepted for presentation at the Society for Immunotherapy of Cancer (SITC).